Date:6/23/2011

For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.Forward-Looking StatementThis press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: the expectations of the purchase of the Shanbally facility, and operational plans for the facility if acquired, and the continued developments of it product candidates. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: obtaining the transfer of the IPPC license from the Irish Environmental Protection Agency; results and timing of current and planned clinical and preclinical studies related to its product candidates; the success in transferring production to the new facility; the content and timing of decisions by the U.S. Food and Drug Administration, the European Commission and other regulatory authorities; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2010 Annual Report on Form 10-K, and the factors contained in BioMarin's reports on Form 10-Q. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin®, Naglazyme®, Kuvan® and Firdapse™ are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.

Contact:Investors

MediaEugeni
'/>"/>

SOURCE BioMarin Pharmaceutical Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. BioMarin to Present at the William Blair Growth Stock Conference
2. BioMarin to Present at the Jefferies Global Healthcare Conference
3. BioMarin to Present at the Bank of America Merrill Lynch Healthcare Conference
4. BioMarin Announces First Quarter 2011 Financial Results
5. BioMarin to Present at the Deutsche Bank Healthcare Conference
6. BioMarin to Present at the Barclays Global Healthcare Conference
7. BioMarin to Present at the Cowen Health Care Conference
8. BioMarin to Present at the Citi Global Healthcare Conference
9. BioMarin Announces Fourth Quarter and Full Year 2010 Financial Results
10. BioMarin Initiates Pivotal Phase 3 Trial for GALNS for the Treatment of MPS IVA
11. BioMarin to Host Fourth Quarter and Full Year 2010 Financial Results